small molecule

XOLREMDI

MAVORIXAFOR

Loss of exclusivityDecember 2038latest FDA-listed patent expiry

CompanyX4 Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand name	XOLREMDI
Active ingredient	MAVORIXAFOR
Strength	100MG
Dosage form	CAPSULE
Route	ORAL
Modality	Small molecule
FDA approval	April 2024
Marketing status	RX

Listed patents

Patent	Expires	Type
11045461	December 2038	product
12115156	December 2038	product
10548889	December 2038	product
11219621	December 2036	use U-3932
10610527	December 2036	use U-3932
10953003	December 2036	product

Regulatory exclusivity

Code	Expires
ODE-480	April 2031
NCE	April 2029

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.